Teva Targets Mid-Single-Digit Revenue Growth Through 2030

Revenue from Teva’s innovative medicines has more than doubled since the company introduced a new growth strategy in 2023. Key products include Austedo, Ajovy and Uzedy; Teva has also recently launched Weltruza.

The company expects growth to continue as it advances its pipeline. Teva said it has seven late-stage pipeline assets with high-value potential, while its innovative pipeline has expanded to ten programs.

“Our R&D engine and commercial excellence are designed to translate proven science into new medicines, with the potential for one new launch annually through 2030,” Chief Executive Richard Francis said.